{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:09:22Z","timestamp":1790392162656,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.08.016","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T15:16:04Z","timestamp":1756134964000},"page":"e41-e49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score\u2013Adjusted Cohort Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1914-0054","authenticated-orcid":false,"given":"Moath","family":"Albliwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-4498","authenticated-orcid":false,"given":"Emily C.","family":"Zabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0428-3505","authenticated-orcid":false,"given":"John","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"El-Asmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Nurse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameed","family":"Bawwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Abuamsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-4512","authenticated-orcid":false,"given":"Yomna","family":"Abu-Farsakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4119-9920","authenticated-orcid":false,"given":"Asad","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heya","family":"Batah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-1539","authenticated-orcid":false,"given":"Ahmed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muaz Alsabbagh","family":"Alchirazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-9241","authenticated-orcid":false,"given":"Akriti G.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-516X","authenticated-orcid":false,"given":"John C","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Balderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3289-2333","authenticated-orcid":false,"given":"Moaath K.","family":"Mustafa Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2025.08.016_bib0001","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","article-title":"Contemporary management of acute myeloid leukemia: a review","volume":"10","author":"Venugopal","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2025.08.016_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.semcancer.2020.11.010","article-title":"Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities","volume":"83","author":"Zhao","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"10.1016\/j.clml.2025.08.016_bib0003","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319366121","article-title":"Aging and comprehensive molecular profiling in acute myeloid leukemia","volume":"121","author":"Li","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.clml.2025.08.016_bib0004","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/S2352-3026(22)00167-3","article-title":"Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia","volume":"9","author":"Short","year":"2022","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.clml.2025.08.016_bib0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.08.016_bib0006","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.clml.2025.08.016_bib0007","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ajh.26917","article-title":"Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60\u2009years with acute myeloid leukemia: assessment of different risk scores","volume":"98","author":"Bachelot","year":"2023","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2025.08.016_bib0008","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3390\/jcm14082759","article-title":"Intensive chemotherapy versus venetoclax-based regimens in elderly patients with acute myeloid leukemia: is the chemotherapy era ending?","volume":"14","author":"Farina","year":"2025","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.clml.2025.08.016_bib0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2025.08.016_bib0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/10428194.2023.2197090","article-title":"Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data","volume":"64","author":"Hoff","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.08.016_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858202","article-title":"Outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: a propensity score-adjusted cohort study","volume":"12","author":"Mustafa Ali","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.08.016_bib0012","unstructured":"Venetoclax + Azacitidine vs. Induction chemotherapy in AML. 2025 05112025 06142025]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT04801797."},{"issue":"22","key":"10.1016\/j.clml.2025.08.016_bib0013","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood.2024027217","article-title":"Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.08.016_bib0014","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","article-title":"Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States","volume":"102","author":"Zeidan","year":"2023","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.clml.2025.08.016_bib0015","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.08.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Informat"},{"issue":"9","key":"10.1016\/j.clml.2025.08.016_bib0017","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/ajh.70000","article-title":"Impact of cytogenetic response to therapy on long-term survival in acute myeloid leukemia","volume":"100","author":"Hanna","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.08.016_bib0019","doi-asserted-by":"crossref","first-page":"e3274","DOI":"10.1002\/hon.3274","article-title":"A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia","volume":"42","author":"Manda","year":"2024","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.08.016_bib0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2024.7026","article-title":"Care patterns and barriers to outpatient Care for adults with AML following intensive chemotherapy at NCCN member institutions","volume":"22","author":"Halpern","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.clml.2025.08.016_bib0021","first-page":"980","article-title":"Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy","volume":"28","author":"Choi","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.clml.2025.08.016_bib0022","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/13696998.2018.1425209","article-title":"Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations","volume":"21","author":"Stein","year":"2018","journal-title":"J Med Econ"},{"issue":"24","key":"10.1016\/j.clml.2025.08.016_bib0023","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"issue":"33","key":"10.1016\/j.clml.2025.08.016_bib0024","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to Cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J Clini Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:52:53Z","timestamp":1768387973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025028848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025028848"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score\u2013Adjusted Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}